|
Canada-0-HYPNOTHERAPY 公司名录
|
公司新闻:
- Engineered antibody fusion proteins for targeted disease therapy
Another fusion protein replaced one Fab of an anti-epithelial growth factor receptor (EGFR) antibody with super mutant IL-2 (sumIL-2), which has reduced IL-2Rα binding activity (Figure 2 B) [54] The resulting molecule inhibited tumor growth in a mouse model of melanoma
- Anti-CD3 scFv-B7. 1 fusion protein expressed on the surface of HeLa . . .
To bridge the gap between cytotoxic T lymphocytes and tumor cells, our objective in this study was to describe the construction and the cell surface-anchored expression of a fusion protein, anti-CD3 scFv-B7 1, derived from inserting a fusion gene encoding anti-CD3 scFv and the extra-cellular domain of B7 1 fused by the splicing by overlap
- Anti‐CD30‐scFv‐Fc‐IL‐2 antibody‐cytokine fusion protein that induces . . .
To deliver IL-2 specifically to CD30 + lymphoma cells, we generated an anti-CD30scFv-IL-2 antibody-cytokine fusion protein that consists of an anti-CD30 scFv antibody for specific tumour cell targeting and of human IL-2 to modulate locally the immune response
- Antibody-IL2 Fusion Proteins for Tumor Targeting
IL2 can be targeted as part of an antibody-cytokine fusion protein to the tumor tissue by a single chain fragment of variable regions (scFv) antibody recognizing a tumor-associated antigen
- Engineered cytokine antibody fusion proteins improve IL-2 delivery to . . .
Here, we introduced a versatile approach to designing intramolecularly assembled single-agent fusion proteins (immunocytokines, ICs) comprising IL-2 and a biasing anti–IL-2 antibody that directs the cytokine toward immune effector cells We optimized IC construction and engineered the cytokine antibody affinity to improve immune bias
- Activation of lymphocytes by anti-CD3 single-chain antibody dimers . . .
Anti-CD3 scFv dimers expressed on the cell surface induced CD25 (IL-2 receptor α-chain) expression and proliferation of splenocytes CT26 tumor cells engineered to express surface scFv
- Anti-CD3 Antibody-Cytokine Fusion Protein, IgG-IL2 - Creative Biolabs
This antibody-cytokine fusion protein was achieved by conjugating fusing the Anti-CD3 IgG to IL2 It was expressed in CHO and purified with affinity chromatography
- Anti-CEA scFv-IL-2 fusion protein. Antibody-cytokine fusion protein is . . .
The resulting fusion protein, designated F39scFv IL-2, effectively targeted IL-2 onto the surface of CEA-expressing tumor cells and consequently introduced a specific cytotoxicity of human
- Efficient T cell activation and expansion - invivogen. com
CD3-CD28 bispecific antibody (bsAb), targeting the human CD3 and CD28 receptors It is a fusion protein dimer comprising tandem single-chain variable fragments (scFv)2 and an IgG1 Fc fragment InvivoGen's bsAb CD3-CD28 mimics the natural cross-linking of these molecules by APCs in vivo and delivers the necessary
- Influence of relative binding affinity on efficacy in a panel of anti . . .
The HSA-scFv fusion protein, in competition with UCHT1 Mab, displayed a curve, which was almost superimposable on that obtained with DT389-scFv(UCHT1) (Fig 5) This suggests that any domain placed N-terminal to the scFv will reduce the binding affinity for antigen
|
|